
Rozanolixizumab for gMG Approved in Japan for Self-Administration
On May 9, Japan’s Pharmaceuticals and Medical Devices Agency followed the European Union’s lead in approving rozanolixizumab (Rystiggo; UCB) for generalized myasthenia gravis via self-administration.1,2 Patients in the country now have the option to use a …